Go Ad-Free
    My Alerts
    Moneycontrol
    Moneycontrol PRO
    HomeNewsAequs

    Jump to

    • See FY17 margin at 17% with downside pressure: Alkem Labs

      The company will work towards increasing volumes in the gastro-intestinal, anti-diabetic and cardio segments, among others, to overcome margin pressures due to industry headwinds, says Prabhat Agrawal, CEO of Alkem Laboratories.

    • Alkem's brush with Germany may not hit profit, revenue:Prabhudas

      There is growing harmonisation between leading regulators across the world and WHO is taking note of the observations made by US FDA on pharma companies everywhere, says Surajit Pal, pharma analyst at Prabhudas Lilladher.

    • Aim is to prevent rampant use of antibiotics: P Lilladher

      Hailing the government's move, Surajit Pal, pharma analyst at Prabhudas Lilladher, says the aim of regulation is to prevent rampant use of antibiotics. He says Abbott is likely to be severely impacted by the move as it has around 15.4 percent exposure to fixed-dosed combinations.

    Advisory Alert: It has come to our attention that certain individuals are representing themselves as affiliates of Moneycontrol and soliciting funds on the false promise of assured returns on their investments. We wish to reiterate that Moneycontrol does not solicit funds from investors and neither does it promise any assured returns. In case you are approached by anyone making such claims, please write to us at grievanceofficer@nw18.com or call on 02268882347